Pfizer gives Phytopharm a boost; pact centers on obesity treatment

Article Abstract:

Phytopharm PLC, based in Britain, UK, signed a licensing deal with Pfizer Inc. that is potentially worth up to $32 million in research funding, license fees and other payments. Under the licensing agreement, Phytopharm gave Pfizer exclusive global rights to an experimental drug against obesity. The compound has been derived from extracts of a plant native to South Africa. The drug has exhibited potential an an appetite suppressant in animal tests, according to Phytopharm Chief Executive Richard Dixey.

Comment:

Signs a licensing deal with Pfizer Inc that gives the latter exclusive global rights to an experimental drug against obesity

United States, Strategic alliances, Anorexigenics, Pfizer Inc., Appetite depressants, Phytopharm PLC, Article

---

Dr. Dexter plays sheriff in DNA gold rush: Wellcome Trust turns fight for gene rights into sharing experience

Article Abstract:

Wellcome Trust chief Michael Dexter is heading a controversial effort to place the results of gene-hunting research in the public domain. In early 1999, Dexter unveiled the SNP Consortium, a joint venture involving Wellcome and major pharmaceutical firms. Those firms have agreed to make genetic data generated under the consortium's auspices public, and that has infuriated some biotechnology companies that have leading rolls in developing proprietary genetic technologies.

Executive changes & profiles, Pharmaceutical Preparations, Statistical Data Included, Management, Pharmaceutical industry, Drugs, Chromosome mapping, Wellcome Trust, Dexter, Michael

---

U.K. urged to boost stem cell research

Article Abstract:

Britain's Chief Medical Officer expert group are recommending that the United Kingdom ease restrictions on cloned embryonic stem cell research.

Government regulation (cont), Research and Development in the Physical, Engineering, and Life Sciences, Research and Testing Services, Medical Research, Brief Article, Stem cells

Similar abstracts:

• Abstracts: Privacy service's impact dismissed. Rogers divisions get ready to bundle. Speed scratch category heats up
• Abstracts: N.S. election ads off to a slow start. Call Centre Conundrum. The little guy that's the local Mr. Big
• Abstracts: P&G swiffers up media coverage. Nestle jumps on orange's appeal
• Abstracts: Toronto dailies hit by transit papers. Carat buys minority stake in Cairns
• Abstracts: Russia gives Iran no clear schedule on nuclear plant. Alcoa in talks on Russia venture. Gazprom board may soon review its stock system

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.